LONGO, MIRIAM
LONGO, MIRIAM
Dipartimento di Scienze Cliniche e di Comunità
$\upalpha$-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study [alpha-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study]
2021 M. Longo, E. Paolini, M. Meroni, L. Duca, I. Motta, A.L. Fracanzani, E. Di Pierro, P. Dongiovanni
Alcohol or gut microbiota : who is the guilty?
2019 M. Meroni, M. Longo, P. Dongiovanni
Cutting-Edge Therapies and Novel Strategies for Acute Intermittent Porphyria: Step-by-Step towards the Solution
2022 M. Longo, E. Paolini, M. Meroni, P. Dongiovanni
DIETARY INTERVENTIONS TARGETING GLUCOSE METABOLISM AND HYPERINSULINEMIA: A NEW TRANSLATIONAL PERSPECTIVE FOR THE MANAGEMENT OF ACUTE INTERMITTENT PORPHYRIA
2023 M. Longo
Expanding the phenotypic spectrum of non-alcoholic fatty liver disease and hypertriglyceridemia
2022 M. Meroni, M. Longo, E. Paolini, G. Tria, M. Ripolone, L. Napoli, M. Moggio, A.L. Fracanzani, P. Dongiovanni
Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease
2020 M. Meroni, M. Longo, P. Dongiovanni
Genetics is of the essence to face NAFLD
2021 M. Meroni, M. Longo, G. Tria, P. Dongiovanni
Genetics, immunity and nutrition boost the switching from nash to hcc
2021 P. Dongiovanni, M. Meroni, M. Longo, S. Fargion, A.L. Fracanzani
Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
2021 M. Meroni, M. Longo, R. Lombardi, E. Paolini, C. Macchi, A. Corsini, C.R. Sirtori, A.L. Fracanzani, M. Ruscica, P. Dongiovanni
MAFLD in COVID-19 patients: an insidious enemy
2020 P. Dongiovanni, M. Meroni, M. Longo, A.L. Fracanzani
MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD
2020 M. Meroni, M. Longo, A.L. Fracanzani, P. Dongiovanni
Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes: Mboat7 reduction and hepatic steatosis
2020 M. Meroni, P. Dongiovanni, M. Longo, F. Carli, G. Baselli, R. Rametta, S. Pelusi, S. Badiali, M. Maggioni, M. Gaggini, A.L. Fracanzani, S. Romeo, S. Gatti, N.O. Davidson, A. Gastaldelli, L. Valenti
Mir-101-3p downregulation promotes fibrogenesis by facilitating hepatic stellate cell transdifferentiation during insulin resistance
2019 M. Meroni, M. Longo, V. Erconi, L. Valenti, S. Gatti, A.L. Fracanzani, P. Dongiovanni
MiRNA signature in NAFLD: A turning point for a non-invasive diagnosis
2018 P. Dongiovanni, M. Meroni, M. Longo, S. Fargion, A.L. Fracanzani
Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending?
2021 M. Longo, M. Meroni, E. Paolini, C. Macchi, P. Dongiovanni
Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD
2020 P. Dongiovanni, M. Meroni, S. Petta, M. Longo, A. Alisi, G. Soardo, L. Valenti, L. Miele, S. Grimaudo, G. Pennisi, G. Antonio, D. Consonni, S. Fargion, A.L. Fracanzani
NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease
2021 S. Grimaudo, P. Dongiovanni, J. Pihlajamaki, M. Eslam, H. Yki-Jarvinen, R.M. Pipitone, G. Baselli, C. Camma, V. Di Marco, M. Enea, M. Longo, G. Pennisi, D. Prati, R. Zito, A.L. Fracanzani, A. Craxi, J. George, S. Romeo, L. Valenti, S. Petta
Nutrition and genetics in NAFLD : The perfect binomium
2020 M. Meroni, M. Longo, A. Rustichelli, P. Dongiovanni
PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients
2019 P. Dongiovanni, M. Meroni, G. Baselli, R.M. Mancina, M. Ruscica, M. Longo, R. Rametta, A. Cespiati, S. Pelusi, N. Ferri, V. Ranzani, V. Nobili, J. Pihlajamaki, A.L. Fracanzani, S. Badiali, S. Petta, S. Fargion, S. Romeo, J. Kozlitina, L. Valenti
Recreating gut-liver axis during NAFLD onset by using a Caco-2/HepG2 co-culture system
2022 M. Meroni, E. Paolini, M. Longo, R. Piciotti, G. Tria, S. Fargion, A. Ludovica Fracanzani, P. Dongiovanni